CELL MEDICA LTD;ベイラー カレッジ オブ メディスン;BAYLOR COLLEGE OF MEDICINE;セル・メディカ・リミテッド;セル・メディカ・リミテッド;ベイラー カレッジ オブ メディスン
发明人:
CLIONA M ROONEY,クリオナ・エム・ルーニー,ANN M LEEN,アン・エム・リーン,JUAN F VERA,ジュアン・エフ・ヴェラ,MINHTRAN V NGO,ミントラン・ヴィ・ヌゴ,RAINER LUDWIG KNAUS,ライナー・ルートヴィヒ・クナウス
申请号：
JP2019211607
公开号：
JP2020054348A
申请日:
2019.11.22
申请国别(地区):
JP
年份:
2020
代理人:
摘要：
PROBLEM TO BE SOLVED: To provide a novel process for expanding T cells, such as autologous T cells, cell populations therefrom, pharmaceutical compositions comprising the cell populations and use of the cells and compositions for treatment, particular the treatment or prophylaxis of virus infection and/or cancer, for example in immune compromised or immune competent human patients.SOLUTION: The present disclosure provides a novel process for in vitro expansion of antigen specific T cells such as autologous or allogeneic antigen specific T cells, comprising the steps: a) culturing a population of autologous PCMB in the presence of: i) dendritic cells which have been pulsed with a peptide/peptide mix relevant to a target antigen(s) or a peptide/peptide mix relevant to a target antigen(s), and ii) at least one cytokine, and b) culturing a population of T cells obtained from step a) in the presence of: i) dendritic cells which have been pulsed with a peptide/peptide mix relevant to a target antigen(s) or autologous antigen presenting T cells (T-APC) cells which have been pulsed with a peptide/peptide mix relevant to a target antigen(s) and an artificial co-stimulatory factor, and ii) optionally a cytokine, wherein the process is characterized in that the process does not employ live virus and/or viral vectors or the use of DNA or RNA encoded antigens or recombinant target antigens in the expansion of the relevant T cell population. The present disclosure relates to cell populations obtained from the process, pharmaceutical compositions comprising the cell populations and use of the cells and compositions for treatment, particular the treatment or prophylaxis of virus infection and/or cancer, for example in immune compromised or immune competent human patients.SELECTED DRAWING: NoneCOPYRIGHT: (C)2020,JPO&INPIT【課題】自己Ｔ細胞などのＴ細胞を増殖させるための新規プロセス、それから得られる細胞集団、前記細胞集団を含む医薬組成物、ならびに治療、特に、たとえば免疫低下もしくは免疫適格ヒト患者におけるウイルス感染および／もしくはガンの治療または予防のための細胞および組成物の使用を提供する。【解決手段】本開示は、自己または同種抗原特異的Ｔ
